Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/10/2023 | 14.76% | DA Davidson | → $44 | Upgrades | Neutral → Buy |
09/27/2023 | 14.76% | Truist Securities | $48 → $44 | Maintains | Buy |
07/31/2023 | 30.41% | Piper Sandler | $42 → $50 | Maintains | Overweight |
07/31/2023 | 25.2% | Truist Securities | $38 → $48 | Maintains | Buy |
05/01/2023 | 19.98% | Piper Sandler | $51 → $46 | Maintains | Overweight |
05/01/2023 | -0.89% | Truist Securities | $43 → $38 | Maintains | Buy |
05/01/2023 | 30.41% | Keefe, Bruyette & Woods | $54 → $50 | Maintains | Outperform |
04/04/2023 | 6.94% | Stephens & Co. | → $41 | Initiates Coverage On | → Equal-Weight |
03/23/2023 | 12.15% | Truist Securities | $52 → $43 | Maintains | Buy |
02/01/2023 | 35.63% | Truist Securities | $60 → $52 | Maintains | Buy |
01/31/2023 | 56.49% | Keefe, Bruyette & Woods | $63 → $60 | Maintains | Outperform |
12/05/2022 | 61.71% | Piper Sandler | → $62 | Reinstates | → Overweight |
10/31/2022 | 56.49% | Truist Securities | $55 → $60 | Maintains | Buy |
10/31/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
09/14/2022 | 43.45% | Truist Securities | $52 → $55 | Maintains | Buy |
07/07/2022 | 25.2% | Raymond James | $50 → $48 | Maintains | Outperform |
04/28/2022 | 30.41% | Raymond James | $57 → $50 | Maintains | Outperform |
12/30/2021 | 48.67% | Stephens & Co. | $56 → $57 | Maintains | Equal-Weight |
11/01/2021 | 48.67% | Raymond James | $55 → $57 | Maintains | Outperform |
09/30/2021 | 46.06% | Stephens & Co. | → $56 | Downgrades | Overweight → Equal-Weight |
04/07/2021 | 56.49% | Raymond James | $46 → $60 | Downgrades | Strong Buy → Outperform |
03/30/2021 | — | DA Davidson | Downgrades | Buy → Neutral | |
02/01/2021 | 19.98% | Raymond James | $44 → $46 | Maintains | Strong Buy |
12/11/2020 | 14.76% | Raymond James | $33 → $44 | Maintains | Strong Buy |
10/26/2020 | -8.71% | Piper Sandler | $28 → $35 | Maintains | Overweight |
10/26/2020 | -13.93% | Raymond James | $27 → $33 | Maintains | Strong Buy |
10/19/2020 | -16.54% | Stephens & Co. | → $32 | Reinstates | → Overweight |
09/30/2020 | -26.97% | Piper Sandler | $29 → $28 | Maintains | Overweight |
09/23/2020 | -29.58% | Raymond James | → $27 | Upgrades | Outperform → Strong Buy |
07/29/2020 | -24.36% | Piper Sandler | → $29 | Reinstates | → Overweight |
07/28/2020 | -21.75% | SunTrust Robinson Humphrey | $29 → $30 | Maintains | Buy |
05/22/2020 | -34.79% | DA Davidson | → $25 | Initiates Coverage On | → Buy |
05/05/2020 | -24.36% | SunTrust Robinson Humphrey | $28 → $29 | Maintains | Buy |
04/06/2020 | -21.75% | SunTrust Robinson Humphrey | $36 → $30 | Maintains | Buy |
01/02/2020 | 30.41% | SunTrust Robinson Humphrey | $47 → $50 | Maintains | Buy |
09/25/2019 | 19.98% | Piper Sandler | $47 → $46 | Maintains | Overweight |
08/27/2019 | 17.37% | SunTrust Robinson Humphrey | $47 → $45 | Maintains | Buy |
07/12/2019 | 17.37% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
01/29/2019 | 25.2% | SunTrust Robinson Humphrey | → $48 | Upgrades | Hold → Buy |
12/18/2018 | 25.2% | Piper Sandler | $49.5 → $48 | Upgrades | Neutral → Overweight |
What is the target price for Ameris (ABCB)?
The latest price target for Ameris (NASDAQ: ABCB) was reported by DA Davidson on October 10, 2023. The analyst firm set a price target for $44.00 expecting ABCB to rise to within 12 months (a possible 14.76% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ameris (ABCB)?
The latest analyst rating for Ameris (NASDAQ: ABCB) was provided by DA Davidson, and Ameris upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Ameris (ABCB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ameris, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ameris was filed on October 10, 2023 so you should expect the next rating to be made available sometime around October 10, 2024.
Is the Analyst Rating Ameris (ABCB) correct?
While ratings are subjective and will change, the latest Ameris (ABCB) rating was a upgraded with a price target of $0.00 to $44.00. The current price Ameris (ABCB) is trading at is $38.34, which is within the analyst's predicted range.